FDA Approves Lipfendra (Enlicitide), the First Oral PCSK9 Inhibitor

The FDA approved Lipfendra (enlicitide) as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol, known as LDL-C, in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia. The FDA described the product as the first oral PCSK9 inhibitor.

Enlicitide is a macrocyclic peptide. Its approval therefore sits within the broader context of other oral peptide milestones: a peptide format completing full FDA review for a chronic, large-population condition.

The date requires careful attention. The FDA Novel Drug Approvals for 2026 page lists the approval date as July 15, 2026, and that is the date used in this post. Merck announced the approval on July 16, 2026, and the FDA press announcement is dated July 17, 2026, so July 17 should not be presented as the approval date without noting that it is the press announcement date.

As with every FDA approval, the decision applies to the specific product, Lipfendra, and the specific indication on its label. It does not extend to compounded formulations, research compounds, or any other use of the molecule.

For researchers, the approval is a regulatory data point for macrocyclic peptide design and for the PCSK9 pathway. The significant finding for this blog is the FDA action itself, recorded on the agency novel approvals list for 2026.